ORIGINAL_ARTICLE
The effect of different digoxin concentrations on heart tissue and antioxidant status in iron-overloaded rats
BACKGROUND: Thalassaemia is a hereditary disorder and has an economic burden on patients and the government. The most prevalent complication in these patients is iron overload which is followed by cardiomyopathy. Digoxin is considered as a treatment against heart failure in thalassaemia. The present study evaluated the effect of two digoxin concentrations on iron content and antioxidative defense in cardiac tissue of iron-overloaded rats.METHODS: The study was conducted on 48 rats which were divided into 6 groups. Group 1 was the control group and did not receive any treatment and group 2 was the iron overload group. In addition groups 3 and 4 were the digoxin control groups which received 1 and 5 mg/kg/day of digoxin, respectively. Groups 5 and 6 received 1 and 5 mg/kg/day of digoxin plus iron-dextran, respectively. After 1 month, malondialdehyde (MDA), superoxide dismutase (SOD), glutathione peroxidase (GPX), and total antioxidant status (TAS) were assessed in cardiac tissues.RESULTS: Co-administration of iron-dextran and digoxin (1 and 5 mg/kg/day) significantly increased SOD and TAS levels (P < 0.0010) and reduced MDA (P < 0.0010) in heart tissue compared to control and iron overload groups. GPX levels significantly reduced in groups 5 and 6 (iron + digoxin 1 (P < 0.0500) and iron + digoxin 5) (P < 0.0010) compared to the iron control group.CONCLUSION: Digoxin remarkably facilitates iron uptake by cardiomyocytes by affecting other channels such as L-type and T-type Ca2+ channels (LTCC and TTCC). Digoxin administration in the iron-overloaded rat model deteriorated antioxidative parameters and increased iron entry into heart tissue at higher doses. Therefore, in patients with beta thalassaemia major, digoxin must be administered with great care and serum iron and ferritin must be regularly monitored.
https://arya.mui.ac.ir/article_10622_49732b6be9221abe4b9f67c3d3c98fe8.pdf
2018-04-21
46
52
10.22122/arya.v14i2.1642
Digoxin
Iron Overload
Superoxide Dismutase
Glutathione Peroxidase
Beydolah
Shahouzehi
1
Assistant Professor, Student Research Committee AND Physiology Research Center, Institute of Basic and Clinical Physiology Sciences, Kerman University of Medical Sciences, Kerman, Iran
AUTHOR
Hamid Reza
Nasri
2
Associate Professor, Cardiovascular Research Center, Institute of Basic and Clinical Physiology Sciences, Kerman University of Medical Sciences, Kerman, Iran
AUTHOR
Yaser
Masoumi-Ardakani
ymab125@gmail.com
3
PhD Candidate, Physiology Research Center, Institute of Basic and Clinical Physiology Sciences, Kerman University of Medical Sciences, Kerman, Iran
LEAD_AUTHOR
Bhagat S, Sarkar PD, Suryakar AN, Hundekar PS. A study on the biomarkers of oxidative stress: The effects of oral therapeutic supplementation on the iron concentration and the product of lipid peroxidation in beta thalassemia major. J Clin Diagn Res 2012; 6(7): 1144-7.
1
Khodaei GH, Farbod N, Zarif B, Nateghi S, Saeidi M. Frequency of thalassemia in Iran and Khorasan Razavi. Int J Pediatr 2013; 1(1): 45-50.
2
Urbanski NK, Beresewicz A. Generation of *OH initiated by interaction of Fe2+ and Cu+ with dioxygen; Comparison with the Fenton chemistry. Acta Biochim Pol 2000; 47(4): 951-62.
3
Walter PB, Fung EB, Killilea DW, Jiang Q, Hudes M, Madden J, et al. Oxidative stress and inflammation in iron-overloaded patients with beta-thalassaemia or sickle cell disease. Br J Haematol 2006; 135(2): 254-63.
4
Gao X, Campian JL, Qian M, Sun XF, Eaton JW. Mitochondrial DNA damage in iron overload. J Biol Chem 2009; 284(8): 4767-75.
5
Handa P, Morgan-Stevenson V, Maliken BD, Nelson JE, Washington S, Westerman M, et al. Iron overload results in hepatic oxidative stress, immune cell activation, and hepatocellular ballooning injury, leading to nonalcoholic steatohepatitis in genetically obese mice. Am J Physiol Gastrointest Liver Physiol 2016; 310(2): G117-G127.
6
Kuo KL, Hung SC, Lee TS, Tarng DC. Iron sucrose accelerates early atherogenesis by increasing superoxide production and upregulating adhesion molecules in CKD. J Am Soc Nephrol 2014; 25(11): 2596-606.
7
Gammella E, Recalcati S, Rybinska I, Buratti P, Cairo G. Iron-induced damage in cardiomyopathy: Oxidative-dependent and independent mechanisms. Oxid Med Cell Longev 2015; 2015: 230182.
8
Engle MA, Erlandson M, Smith CH. Late cardiac complications of chronic, severe, refractory anemia with hemochromatosis. Circulation 1964; 30:
9
Zurlo MG, De Stefano P, Borgna-Pignatti C, Di Palma A, Piga A, Melevendi C, et al. Survival and causes of death in thalassaemia major. Lancet 1989; 2(8653): 27-30.
10
Ladis V, Chouliaras G, Berdousi H, Kanavakis E, Kattamis C. Longitudinal study of survival and causes of death in patients with thalassemia major in Greece. Ann N Y Acad Sci 2005; 1054: 445-50.
11
Kremastinos DT, Farmakis D, Aessopos A, Hahalis G, Hamodraka E, Tsiapras D, et al. Beta-thalassemia cardiomyopathy: History, present considerations, and future perspectives. Circ Heart Fail 2010; 3(3): 451-8.
12
Lelie`vre LG, Lechat P. Mechanisms, manifestations, and management of digoxin toxicity. Heart Metab 2007; 35: 9-11.
13
Kurian M. The effect of digitalis on the heart-an update. J Pharm Sci Res 2015; 7(10): 861-3.
14
Tsushima RG, Wickenden AD, Bouchard RA, Oudit GY, Liu PP, Backx PH. Modulation of iron uptake in heart by L-type Ca2+ channel modifiers: Possible implications in iron overload. Circ Res 1999; 84(11): 1302-9.
15
Oudit GY, Sun H, Trivieri MG, Koch SE, Dawood F, Ackerley C, et al. L-type Ca2+ channels provide a major pathway for iron entry into cardiomyocytes in iron-overload cardiomyopathy. Nat Med 2003; 9(9): 1187-94.
16
Kumfu S, Chattipakorn S, Chinda K, Fucharoen S, Chattipakorn N. T-type calcium channel blockade improves survival and cardiovascular function in thalassemic mice. Eur J Haematol 2012; 88(6): 535-48.
17
Chattipakorn N, Kumfu S, Fucharoen S, Chattipakorn S. Calcium channels and iron uptake into the heart. World J Cardiol 2011; 3(7): 215-8.
18
Chen MP, Cabantchik ZI, Chan S, Chan GC, Cheung YF. Iron overload and apoptosis of HL-1 cardiomyocytes: Effects of calcium channel blockade. PLoS One 2014; 9(11): e112915.
19
Kumfu S, Chattipakorn SC, Fucharoen S, Chattipakorn N. Dual T-type and L-type calcium channel blocker exerts beneficial effects in attenuating cardiovascular dysfunction in iron-overloaded thalassaemic mice. Exp Physiol 2016; 101(4): 521-39.
20
Nasri HR, Shahouzehi B, Masoumi-Ardakani Y, Iranpour M. Effects of digoxin on cardiac iron content in rat model of iron overload. ARYA Atheroscler 2016; 12(4): 180-4.
21
Lim CS, Vaziri ND. The effects of iron dextran on the oxidative stress in cardiovascular tissues of rats with chronic renal failure. Kidney Int 2004; 65(5): 1802-9.
22
Wood JC, Enriquez C, Ghugre N, Otto-Duessel M, Aguilar M, Nelson MD, et al. Physiology and pathophysiology of iron cardiomyopathy in thalassemia. Ann N Y Acad Sci 2005; 1054: 386-95.
23
Mishra AK, Tiwari A. Iron overload in Beta thalassaemia major and intermedia patients. Maedica (Buchar) 2013; 8(4): 328-32.
24
Sattari M, Sheykhi D, Nikanfar A, Pourfeizi AH, Nazari M, Dolatkhah R, et al. The financial and social impact of thalassemia and its treatment in Iran. Pharm Sci 2012; 18(3): 171-6.
25
Kumfu S, Chattipakorn S, Srichairatanakool S, Settakorn J, Fucharoen S, Chattipakorn N. T-type calcium channel as a portal of iron uptake into cardiomyocytes of beta-thalassemic mice. Eur J Haematol 2011; 86(2): 156-66.
26
Kumfu S, Chattipakorn S, Fucharoen S, Chattipakorn N. Ferric iron uptake into cardiomyocytes of b-thalassemic mice is not through calcium channels. Drug Chem Toxicol 2013; 36(3): 329-34.
27
Arispe N, Diaz JC, Simakova O, Pollard HB. Heart failure drug digitoxin induces calcium uptake into cells by forming transmembrane calcium channels. Proc Natl Acad Sci U S A 2008; 105(7): 2610-5.
28
de Valk B, Marx JJ. Iron, atherosclerosis, and ischemic heart disease. Arch Intern Med 1999; 159(14): 1542-8.
29
Lee TS, Shiao MS, Pan CC, Chau LY. Iron-deficient diet reduces atherosclerotic lesions in apoE-deficient mice. Circulation 1999; 99(9): 1222-9.
30
ORIGINAL_ARTICLE
Periopathogens in atherosclerotic plaques of patients with both cardiovascular disease and chronic periodontitis
BACKGROUND: Atherosclerosis and periodontitis are both chronic inflammatory diseases. Although a strong relationship between the two has already been established, the underlying mechanism is unknown. The present study was conducted aiming to detect the deoxyribonucleic acid (DNA) of Aggregatibacter actinomycetemcomitans (A.a), Campylobacter rectus (C.r), and Porphyromonas gingivalis (P.g) in subgingival and atherosclerotic plaques of patients with both chronic periodontitis and cardiovascular disease (CVD).METHODS: In this cross sectional study, patients with coronary artery disease (CAD) and moderate to severe periodontitis which were scheduled for coronary artery bypass grafting (CABG) were enrolled in the study. The subgingival plaques were collected before surgery. All samples were examined for the detection of selected periopathogens using polymerase chain reaction (PCR).RESULTS: The subgingival and atherosclerotic plaque samples of 23 patients were examined. The DNA of P.g, A.a, and C.r were found to be positive in 43.47%, 43.47%, and 78.26% of subgingival plaques, and 13.04%, 17.39%, and 8.69% of atherosclerotic plaques, respectively. In all cases, the bacterial species found in atherosclerotic plaques were also found in the subgingival plaques of the same patient.CONCLUSION: This study demonstrated the presence of periopathogens in atherosclerotic plaques of patients with chronic periodontitis. More studies are required to ascertain the exact role of these periopathogens in atherosclerotic plaque formation.
https://arya.mui.ac.ir/article_10623_e14cdd92efe55e42b155bdd896b7da59.pdf
2018-04-21
53
57
10.22122/arya.v14i2.1504
Atherosclerosis
Coronary Artery Disease
Chronic Periodontitis
Porphyromonas Gingivalis
Aggregatibacter Actinomycetemcomitans
Campylobacter Rectus
Fazele
Atarbashi-Moghadam
1
Assistant Professor, Department of Periodontics, School of Dentistry, Shahid Beheshti University of Medical Sciences, Tehran, Iran
AUTHOR
Seyed Rohollah
Havaei
marty_zl@yahoo.com
2
Assistant Professor, Department of Endodontics, School of Dentistry, Khorasgan Branch, Islamic Azad University, Isfahan, Iran
LEAD_AUTHOR
Seyed Asghar
Havaei
3
Professor, Department of Microbiology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
AUTHOR
Nafiseh Sadat
Hosseini
4
PhD Candidate, Department of Biotechnology, Shahid Beheshti University of Medical Sciences, Tehran, Iran
AUTHOR
Gholamreza
Behdadmehr
5
Department of Cardiology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
AUTHOR
Saede
Atarbashi-Moghadam
6
Assistant Professor, Department of Oral and Maxillofacial Pathology, School of Dentistry, Shahid Beheshti University of Medical Sciences, Tehran, Iran
AUTHOR
Ainamo J, Loe H. Anatomical characteristics of gingiva. A clinical and microscopic study of the free and attached gingiva. J Periodontol 1966; 37(1): 5-13.
1
Chistiakov DA, Orekhov AN, Bobryshev YV. Links between atherosclerotic and periodontal disease. Exp Mol Pathol 2016; 100(1): 220-35.
2
Kjellstrom B, Ryden L, Klinge B, Norhammar A. Periodontal disease-important to consider in cardiovascular disease prevention. Expert Rev Cardiovasc Ther 2016; 14(9): 987-9.
3
Gaetti-Jardim E Jr, Marcelino SL, Feitosa AC, Romito GA, Avila-Campos MJ. Quantitative detection of periodontopathic bacteria in atherosclerotic plaques from coronary arteries. J Med Microbiol 2009; 58(Pt 12): 1568-75.
4
Szulc M, Kustrzycki W, Janczak D, Michalowska D, Baczynska D, Radwan-Oczko M. Presence of Periodontopathic Bacteria DNA in Atheromatous Plaques from Coronary and Carotid Arteries. Biomed Res Int 2015; 2015: 825397.
5
Campbell LA, Rosenfeld ME. Infection and atherosclerosis development. Arch Med Res 2015; 46(5): 339-50.
6
Pourmoghaddas Z, Sadeghi M, Hekmatnia A, Sanei H, Tavakoli B, et al. Different Measurements of the obesity, adiponectin and coronary heart disease: A single-center study from Isfahan. J ResMed Sci 2012; 17(Spec 2): S218-S222.
7
Nesarhoseini V, Khosravi M. Periodontitis as a risk factor in non-diabetic patients with coronary artery disease. ARYA Atheroscler 2010; 6(3): 106-11.
8
Haynes WG, Stanford C. Periodontal disease and atherosclerosis: From dental to arterial plaque. Arterioscler Thromb Vasc Biol 2003; 23(8): 1309-11.
9
Georges JL, Rupprecht HJ, Blankenberg S, Poirier O, Bickel C, Hafner G, et al. Impact of pathogen burden in patients with coronary artery disease in relation to systemic inflammation and variation in genes encoding cytokines. Am J Cardiol 2003; 92(5): 515-21.
10
World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects. JAMA 2013; 310(20): 2191-4.
11
Mahendra J, Mahendra L, Kurian VM, Jaishankar K, Mythilli R. 16S rRNA-based detection of oral pathogens in coronary atherosclerotic plaque. Indian J Dent Res 2010; 21(2): 248-52.
12
Howell TH, Ridker PM, Ajani UA, Hennekens CH, Christen WG. Periodontal disease and risk of subsequent cardiovascular disease in U.S. male physicians. J Am Coll Cardiol 2001; 37(2): 445-50.
13
Hansen GM, Egeberg A, Holmstrup P, Hansen PR. Relation of Periodontitis to risk of cardiovascular and all-cause mortality (from a Danish Nationwide Cohort Study). Am J Cardiol 2016; 118(4): 489-93.
14
Cairo F, Gaeta C, Dorigo W, Oggioni MR, Pratesi C, Pini Prato GP, et al. Periodontal pathogens in
15
atheromatous plaques. A controlled clinical and laboratory trial. J Periodontal Res 2004; 39(6): 442-6.
16
Aimetti M, Romano F, Nessi F. Microbiologic analysis of periodontal pockets and carotid atheromatous plaques in advanced chronic periodontitis patients. J Periodontol 2007; 78(9): 1718-23.
17
Aquino AR, Lima KC, Paiva MS, Rocas IN, Siqueira JF Jr. Molecular survey of atheromatous plaques for the presence of DNA from periodontal bacterial pathogens, archaea and fungi. J Periodontal Res 2011; 46(3): 303-9.
18
Pucar A, Milasin J, Lekovic V, Vukadinovic M, Ristic M, Putnik S, et al. Correlation between atherosclerosis and periodontal putative pathogenic bacterial infections in coronary and internal mammary arteries. J Periodontol 2007; 78(4): 677-82.
19
Marcelino SL, Gaetti-Jardim E Jr, Nakano V, Canonico LA, Nunes FD, Lotufo RF, et al. Presence of periodontopathic bacteria in coronary arteries from patients with chronic periodontitis. Anaerobe 2010; 16(6): 629-32.
20
Toyofuku T, Inoue Y, Kurihara N, Kudo T, Jibiki M, Sugano N, et al. Differential detection rate of periodontopathic bacteria in atherosclerosis. Surg Today 2011; 41(10): 1395-400.
21
Schenkein HA, Barbour SE, Berry CR, Kipps B, Tew JG. Invasion of human vascular endothelial cells by Actinobacillus actinomycetemcomitans via the receptor for platelet-activating factor. Infect Immun 2000; 68(9): 5416-9.
22
ORIGINAL_ARTICLE
Methods of sampling and sample size determination of a comprehensive integrated community-based interventional trial: Isfahan Healthy Heart Program
BACKGROUND: The aim of this study was describing the sampling methods and sample size of the Isfahan Healthy Heart Program (IHHP) and its sub-studies in focus.METHODS: The IHHP was carried out between 2000 and 2007 in urban and rural areas in 3 districts, namely Isfahan and Najafabad (as the intervention areas), and Arak (as the reference area), Iran. It consisted of the 3 phases of baseline surveys during 2000-2001, interventions between 2002 and 2005, and post-intervention surveys during 2006-2007 on 4 target groups (adults, health professionals, cardiac patients, children, and adolescents). During 2002 to 2005, 4 evaluation studies were conducted to evaluate short-term results. An ongoing cohort study entitled the Isfahan Cohort Study was performed on those aged ≥ 35 years at baseline in 2001 to access the risk of cardiovascular disease (CVD) occurrence.RESULTS: Using stratified random cluster methods, 12514, 5891, 4793, 6096, 3012, and 9572 adults and 1946, 1999, 1427, 1223, 389, and 1992 adolescents were chosen in the 1st to 3rd phases. Furthermore, simple random sampling was used for selecting 923, 694, 1000, and 2015 health professionals and 814, 452, 420, and 502 cardiac patients. A multistage sampling method was adopted for the collection of samples from parents of preschoolers and primary school children aged 2-10 years, adolescents’ parents, and some teachers. A prospective cohort study was started on 6504 eligible individuals.CONCLUSION: The IHHP, as a comprehensive community-based interventional trial in Iran, among the few population-based studies around the world, has reasonable sampling methods and sample size.
https://arya.mui.ac.ir/article_10624_b6bb40c616c46d9936b20968a2eb9141.pdf
2018-04-21
58
70
10.22122/arya.v14i2.1488
Cardiovascular Disease
Sample Size
Sampling Design
Isfahan Healthy Heart Program
Fatemeh
Nouri
1
PhD Candidate, Isfahan Cardiovascular Research Center AND Interventional Cardiology Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
AUTHOR
Awat
Feizi
awat_feiz@hlth.mui.ac.ir
2
Professor, Cardiac Rehabilitation Research Center, Cardiovascular Research Institute AND Department of Biostatistics and Epidemiology, School of Health, Isfahan University of Medical Sciences, Isfahan, Iran
LEAD_AUTHOR
Noushin
Mohammadifard
nmohammadifard@gmail.com
3
Heart Failure Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
AUTHOR
Nizal
Sarrafzadegan
nsarrafzadegan@gmail.com
4
Professor, Isfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
AUTHOR
Gaziano T, Reddy KS, Paccaud F, Horton S, Chaturvedi V. Cardiovascular Disease. In: Jamison DT, Breman JG, Measham AR, et al., editors. Disease Control Priorities in Developing Countries. 2nd ed. Washington, DC: World Bank Publications; 2006.
1
Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006; 3(11): e442.
2
Khosravi A, Aghamohamadi S, Kazemi E, Pour Malek F, Shariati M. Mortality profile in Iran (29 provinces) over the years 2006 to 2010. Tehran, Iran: Ministry of Health and Medical Education; 2013. [In Persian].
3
Abegunde DO, Mathers CD, Adam T, Ortegon M, Strong K. The burden and costs of chronic diseases in low-income and middle-income countries. Lancet 2007; 370(9603): 1929-38.
4
Talaei M, Sarrafzadegan N, Sadeghi M, Oveisgharan S, Marshall T, Thomas GN, et al. Incidence of cardiovascular diseases in an Iranian population: The Isfahan Cohort Study. Arch Iran Med 2013; 16(3): 138-44.
5
Pennant M, Davenport C, Bayliss S, Greenheld W, Marshall T, Hyde C. Community programs for the prevention of cardiovascular disease: a systematic review. Am J Epidemiol 2010; 172(5): 501-16.
6
Farquhar JW, Fortmann SP, Maccoby N, Haskell WL, Williams PT, Flora JA, et al. The stanford five-city project: Design and methods. Am J Epidemiol 1985; 122(2): 323-34.
7
Luepker RV, Murray DM, Jacobs DR Jr, Mittelmark MB, Bracht N, Carlaw R, et al. Community education for cardiovascular disease prevention: Risk factor changes in the Minnesota Heart Health Program. Am J Public Health 1994; 84(9): 1383-93.
8
Vartiainen E, Puska P, Pekkanen J, Tuomilehto J, Jousilahti P. Changes in risk factors explain changes in mortality from ischaemic heart disease in Finland. BMJ 1994; 309(6946): 23-7.
9
Luepker RV, Rastam L, Hannan PJ, Murray DM, Gray C, Baker WL, et al. Community education for cardiovascular disease prevention. Morbidity and mortality results from the Minnesota Heart Health Program. Am J Epidemiol 1996; 144(4): 351-62.
10
Fortmann SP, Varady AN. Effects of a community-
11
wide health education program on cardiovascular disease morbidity and mortality: The Stanford Five-City Project. Am J Epidemiol 2000; 152(4): 316-23.
12
Nissinen A, Berrios X, Puska P. Community-based noncommunicable disease interventions: Lessons from developed countries for developing ones. Bull World Health Organ 2001; 79(10): 963-70.
13
Kelishadi R, Pashmi M, Ahmadi R, Mohammad Zadeh M, Sadry G, Sarrafzadegan N. Healthy Heart Program: Heart health promotion from childhood. J Qazvin Univ Med Sci 2003; 7(2): 15-26.
14
Sarraf-Zadegan N, Sadri G, Malek AH, Baghaei M, Mohammadi FN, Shahrokhi S, et al. Isfahan Healthy Heart Programme: A comprehensive integrated community-based programme for cardiovascular disease prevention and control. Design, methods and initial experience. Acta Cardiol 2003; 58(4): 309-20.
15
Sarrafzadegan N, Baghaei A, Sadri G, Kelishadi R, Malekafzali H, Boshtam M, et al. Isfahan healthy heart program: Evaluation of comprehensive, community-based interventions for non-communicable disease prevention. Prevention and Control 2006; 2(2): 73-84.
16
Sadeghi M, Roohafza H, Shirani S, Poormoghadas M, Kelishadi R, Baghaii A, et al. Diabetes and associated cardiovascular risk factors in Iran: The Isfahan Healthy Heart Programme. Ann Acad Med Singapore 2007; 36(3): 175-80.
17
Sarrafzadegan N, Kelishadi R, Baghaei A, Hussein Sadri G, Malekafzali H, Mohammadifard N, et al. Metabolic syndrome: An emerging public health problem in Iranian women: Isfahan Healthy Heart Program. Int J Cardiol 2008; 131(1): 90-6.
18
Bahonar A, Khosravi A, Esmaeelian H, Babak A, Sarrafzadeghan N, Rahmati M, et al. Methods of implementing the operational phases of the health professionals education project-Isfahan Healthy Heart Program (IHHP-HPEP). ARYA Atheroscler 2009; 5(3).
19
Sarrafzadegan N, Kelishadi R, Esmaillzadeh A, Mohammadifard N, Rabiei K, Roohafza H, et al. Do lifestyle interventions work in developing countries? Findings from the Isfahan Healthy Heart Program in the Islamic Republic of Iran. Bull World Health Organ 2009; 87(1): 39-50.
20
Baghaei A, Sarrafzadegan N, Rabiei K, Gharipour M, Tavasoli AA, Shirani S, et al. How effective are strategies for non-communicable disease prevention and control in a high risk population in a developing country? Isfahan Healthy Heart Programme. Arch Med Sci 2010; 6(1): 24-31.
21
Khosravi A, Kiani Mehr G, Kelishadi R, Shirani S, Gharipour M, Tavassoli A, et al. The impact of a 6-year comprehensive community trial on the awareness, treatment and control rates of hypertension in Iran: Experiences from the Isfahan healthy heart program. BMC Cardiovascular Disorders 2010; 10: 61.
22
Sadeghi M, Ramezani J, Sanei H, Rabeiee K, Gharipoor M, Toghianifar N. Adherence to evidence-based therapies and modifiable risk factors in patients with coronary artery disease-the hlcp project. ARYA Atheroscler 2006; 2(3).
23
Gharipour M, Kelishadi R, Toghianifar N, Mackie M, Yazdani M, Noori F. Sex based pharmacological treatment in patients with metabolic syndrome: Findings from the Isfahan healthy heart program. Afr J Pharm Pharmacol 2011; 5(3): 311-6.
24
Najafian J, Toghianifar N, Mohammadifard N, Nouri F. Association between sleep duration and metabolic syndrome in a population-based study: Isfahan Healthy Heart Program. J Res Med Sci 2011; 16(6): 801-6.
25
Sarrafzadegan N, Rabiei K, Alavi M, Abedi H, Zarfeshani S. How can the results of a qualitative process evaluation be applied in management, improvement and modification of a preventive community trial? The IHHP Study. Arch Public Health 2011; 69: 9.
26
Sarrafzadegan N, Talaei M, Sadeghi M, Kelishadi R, Oveisgharan S, Mohammadifard N, et al. The Isfahan cohort study: Rationale, methods and main findings. J Hum Hypertens 2011; 25(9): 545-53.
27
Kelishadi R, Mohammadifard N, Sarrazadegan N, Nouri F, Pashmi R, Bahonar A, et al. The effects of a comprehensive community trial on cardiometabolic risk factors in adolescents: Isfahan Healthy Heart Program. ARYA Atheroscler 2012; 7(4): 184-90.
28
Mohammadifard N, Sarrafzadegan N, Nouri F, Sajjadi F, Alikhasi H, Maghroun M, et al. Using factor analysis to identify dietary patterns in Iranian adults: Isfahan Healthy Heart Program. Int J Public Health 2012; 57(1): 235-41.
29
Ahmadi A, Gharipour M, Nouri F, Sarrafzadegan N. Metabolic syndrome in Iranian youths: A population-based study on junior and high schools students in rural and urban areas. J Diabetes Res 2013; 2013: 738485.
30
Sarrafzadegan N, Gharipour M, Sadeghi M, Nouri F, Asgary S, Zarfeshani S. Differences in the prevalence of metabolic syndrome in boys and girls based on various definitions. ARYA Atheroscler 2013; 9(1): 70-6.
31
Sarrafzadegan N, Kelishadi R, Sadri G, Malekafzali H, Pourmoghaddas M, Heidari K, et al. Outcomes of a comprehensive healthy lifestyle program on cardiometabolic risk factors in a developing country: The Isfahan Healthy Heart Program. Arch Iran Med 2013; 16(1): 4-11.
32
Ahmadi A, Gharipour M, Nouri F, Kelishadi R, Sadeghi M, Sarrafzadegan N. Association between adolescence obesity and metabolic syndrome: Evidence from Isfahan Healthy Heart Program. Indian J Endocrinol Metab 2014; 18(4): 569-73.
33
Najafian J, Mohammadifard N, Naeini FF, Nouri F. Relation between usual daily walking time and metabolic syndrome. Niger Med J 2014; 55(1): 29-33.
34
Roohafza H, Khani A, Sadeghi M, Bahonar A, Sarrafzadegan N. Health volunteers' knowledge of cardiovascular disease prevention and healthy lifestyle following a community trial: Isfahan healthy heart program. J Educ Health Promot 2014; 3: 59.
35
Nouri F, Sarrafzadegan N, Mohammadifard N, Sadeghi M, Mansourian M. Intake of legumes and the risk of cardiovascular disease: Frailty modeling of a prospective cohort study in the Iranian middle-aged and older population. Eur J Clin Nutr 2016; 70(2): 217-21.
36
Mohammadifard N, Sajjadi F, Maghroun M, Alikhasi H, Nilforoushzadeh F, Sarrafzadegan N. Validation of a simplified food frequency questionnaire for the assessment of dietary habits in Iranian adults: Isfahan Healthy Heart Program, Iran. ARYA Atheroscler 2015; 11(2): 139-46.
37
Hosseini E, Lachat UGent C, Mohammadifard N, Sarrafzadegan N, UGent K. Associations of dietary glycemic index and glycemic load with glucose intolerance in Iranian adults. Int J Diabetes Dev Ctries 2014; 34(2): 89-94.
38
Mohammadifard N, Mansourian M, Sajjadi F, Maghroun M, Pourmoghaddas A, Yazdekhasti N, et al. Association of glycaemic index and glycaemic load with metabolic syndrome in an Iranian adult population: Isfahan Healthy Heart Program. Nutr Diet 2017; 74(1): 61-6.
39
Azizi F, Ghanbarian A, Momenan AA, Hadaegh F, Mirmiran P, Hedayati M, et al. Prevention of non-communicable disease in a population in nutrition transition: Tehran Lipid and Glucose Study phase II. Trials 2009; 10: 5.
40
Mohammadifard N, Kelishadi R, Safavi M, Sarrafzadegan N, Sajadi F, Sadri GH, et al. Effect of a community-based intervention on nutritional behaviour in a developing country setting: The Isfahan Healthy Heart Programme. Public Health Nutr 2009; 12(9): 1422-30.
41
Rabiei K, Kelishadi R, Sarrafzadegan N, Abedi HA, Alavi M, Heidari K, et al. Process evaluation of a community-based program for prevention and control of non-communicable disease in a developing country: The Isfahan Healthy Heart Program, Iran. BMC Public Health 2009; 9: 57.
42
Sarrafzadegan N, Azadbakht L, Mohammadifard N, Esmaillzadeh A, Safavi M, Sajadi F, et al. Do lifestyle interventions affect dietary diversity score in the general population? Public Health Nutr 2009; 12(10): 1924-30.
43
ORIGINAL_ARTICLE
Cardiac and renal fibrosis and oxidative stress balance in lipopolysaccharide-induced inflammation in male rats
BACKGROUND: Subclinical inflammation induced by persistent exposure to lipopolysaccharide (LPS) is found in some clinical conditions such as obesity or diabetes. This study aimed to investigate the effect of recurrent LPS exposure on inflammatory markers, oxidative stress balance and cardiac and renal fibrosis in male rats.METHODS: Male Wistar rats were divided into control and LPS-treated. LPS (10 mg/kg/week) was injected intraperitoneally. After 4 weeks, left ventricles and kidneys were homogenized and stained with hematoxylin and eosin (H&E) and Masson trichrome for histological examination. Serum levels of nitrite, interleukin 6 (IL-6) and tumor necrosis factor-α (TNF-α) were measured and total thiol, malondialdehyde (MDA), superoxide dismutase (SOD) and catalase were evaluated in the heart and kidney homogenates.RESULTS: Serum inflammatory markers were higher in LPS group than control (nitrite: 37.0 ± 2.2 vs. 25.5 ± 1.9 µmol/l; IL-6: 84 ± 3 vs. 98.0 ± 4.4 pg/ml; TNF-α: 75.5 ± 4.9 vs. 85.3 ± 4.7 pg/ml; respectively, P < 0.050). Evaluation of total thiol concentration (heart: 10.0 ± 0.9 vs. 22.5 ± 1.2; kidney: 7.0 ± 0.5 vs. 27.8 ± 3.1 nmol/g tissue, respectively), catalase (heart: 0.18 ± 0.03 vs. 0.66 ± 0.04; kidney: 0.17 ± 0.03 vs. 0.73 ± 0.03, U/g tissue, respectively) and SOD (heart: 8.01 ± 0.70 vs. 12.3 ± 0.4; kidney: 7.02 ± 0.60 vs. 12.0 ± 0.2, U/g tissue, respectively) showed lower levels in LPS-treated group compared to control; while MDA concentration in LPS group was higher than control (P < 0.05). Histopathological examination in LPS-treated group indicated infiltration of inflammatory cells and more collagen deposition in left ventricle wall and kidney compared to control group.CONCLUSION: We concluded that in clinical conditions with chronic LPS, cardiac and renal fibrosis occurs even in absence of preceding tissue injury due to imbalances in oxidative stress.
https://arya.mui.ac.ir/article_10625_019ba957afe8c4a70c8688f96d86e372.pdf
2018-04-21
71
77
10.22122/arya.v14i2.1550
Inflammation, Lipopolysaccharide
Oxidative Stress
Heart
Kidney
Fereshteh
Asgharzadeh
1
PhD Candidate, Department of Physiology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
AUTHOR
Rahimeh
Bargi
2
PhD Candidate, Department of Physiology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
AUTHOR
Mahmoud
Hosseini
3
Neurocognitive Research Center AND School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
AUTHOR
Mehdi
Farzadnia
4
Associate Professor, Departments of Pathology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
AUTHOR
Majid
Khazaei
khazaei@med.mui.ac.ir
5
Professor, Neurogenic Inflammation Research Center AND School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
LEAD_AUTHOR
Ferrero-Miliani L, Nielsen OH, Andersen PS, Girardin SE. Chronic inflammation: Importance of NOD2 and NALP3 in interleukin-1beta generation. Clin Exp Immunol 2007; 147(2): 227-35.
1
Asgharzadeh F, Rouzbahani R, Khazaei M. Chronic low-grade inflammation: Etiology and its effects. J Isfahan Med Sch 2016; 34(379): 408-21.
2
Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007; 56(7): 1761-72.
3
Shalapour S, Karin M. Immunity, inflammation, and cancer: An eternal fight between good and evil. J Clin Invest 2015; 125(9): 3347-55.
4
Tahergorabi Z, Khazaei M. The relationship between inflammatory markers, angiogenesis, and obesity. ARYA Atheroscler 2013; 9(4): 247-53.
5
Burgoyne JR, Mongue-Din H, Eaton P, Shah AM. Redox signaling in cardiac physiology and pathology. Circ Res 2012; 111(8): 1091-106.
6
Petersen AM, Pedersen BK. The anti-inflammatory effect of exercise. J Appl Physiol (1985) 2005; 98(4): 1154-62.
7
Manco M, Putignani L, Bottazzo GF. Gut microbiota, lipopolysaccharides, and innate immunity in the pathogenesis of obesity and cardiovascular risk. Endocr Rev 2010; 31(6): 817-44.
8
Shen J, Obin MS, Zhao L. The gut microbiota, obesity and insulin resistance. Mol Aspects Med 2013; 34(1): 39-58.
9
Tahergorabi Z, Khazaei M, Moodi M, Chamani E. From obesity to cancer: A review on proposed mechanisms. Cell Biochem Funct 2016; 34(8): 533-45.
10
Sallam N, Khazaei M, Laher I. Effect of moderate-intensity exercise on plasma C-reactive protein and aortic endothelial function in type 2 diabetic mice. Mediators Inflamm 2010; 2010: 149678.
11
Beutler B, Rietschel ET. Innate immune sensing and its roots: The story of endotoxin. Nat Rev Immunol 2003; 3(2): 169-76.
12
Frantz S, Kobzik L, Kim YD, Fukazawa R, Medzhitov R, Lee RT, et al. Toll4 (TLR4) expression in cardiac myocytes in normal and failing myocardium. J Clin Invest 1999; 104(3): 271-80.
13
Court O, Kumar A, Parrillo JE, Kumar A. Clinical review: Myocardial depression in sepsis and septic shock. Crit Care 2002; 6(6): 500-8.
14
Krishnagopalan S, Kumar A, Parrillo JE, Kumar A. Myocardial dysfunction in the patient with sepsis. Curr Opin Crit Care 2002; 8(5): 376-88.
15
Doi K, Leelahavanichkul A, Yuen PS, Star RA. Animal models of sepsis and sepsis-induced kidney injury. J Clin Invest 2009; 119(10): 2868-78.
16
Lew WY, Bayna E, Molle ED, Dalton ND, Lai NC, Bhargava V, et al. Recurrent exposure to subclinical lipopolysaccharide increases mortality and induces cardiac fibrosis in mice. PLoS One 2013; 8(4): e61057.
17
Lew WY, Bayna E, Dalle Molle E, Contu R, Condorelli G, Tang T. Myocardial fibrosis induced by exposure to subclinical lipopolysaccharide is associated with decreased miR-29c and enhanced NOX2 expression in mice. PLoS One 2014; 9(9): e107556.
18
Elmi S, Sallam NA, Rahman MM, Teng X, Hunter AL, Moien-Afshari F, et al. Sulfaphenazole treatment restores endothelium-dependent vasodilation in diabetic mice. Vascul Pharmacol 2008; 48(1): 1-8.
19
Khazaei M, Fallahzadeh AR, Sharifi MR, Afsharmoghaddam N, Javanmard SH, Salehi E. Effects of diabetes on myocardial capillary density and serum angiogenesis biomarkers in male rats. Clinics (Sao Paulo) 2011; 66(8): 1419-24.
20
Nematollahi S, Nematbakhsh M, Haghjooyjavanmard S, Khazaei M, Salehi M. Inducible nitric oxide synthase modulates angiogenesis in ischemic hindlimb of rat. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2009; 153(2): 125-9.
21
Janero DR. Malondialdehyde and thiobarbituric acid-reactivity as diagnostic indices of lipid peroxidation and peroxidative tissue injury. Free Radic Biol Med 1990; 9(6): 515-40.
22
Hosseinzadeh H, Sadeghnia HR. Safranal, a constituent of Crocus sativus (saffron), attenuated cerebral ischemia induced oxidative damage in rat hippocampus. J Pharm Pharm Sci 2005; 8(3): 394-9.
23
Aebi H. Catalase in vitro. Methods Enzymol 1984; 105: 121-6.
24
Warren HS, Fitting C, Hoff E, Adib-Conquy M, Beasley-Topliffe L, Tesini B, et al. Resilience to bacterial infection: Difference between species could be due to proteins in serum. J Infect Dis 2010; 201(2): 223-32.
25
Copeland S, Warren HS, Lowry SF, Calvano SE, Remick D. Acute inflammatory response to endotoxin in mice and humans. Clin Diagn Lab Immunol 2005; 12(1): 60-7.
26
Seki E, De Minicis S, Osterreicher CH, Kluwe J, Osawa Y, Brenner DA, et al. TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat Med 2007; 13(11): 1324-32.
27
Pulskens WP, Rampanelli E, Teske GJ, Butter LM, Claessen N, Luirink IK, et al. TLR4 promotes fibrosis but attenuates tubular damage in progressive renal injury. J Am Soc Nephrol 2010; 21(8): 1299-308.
28
Blyszczuk P, Kania G, Dieterle T, Marty RR, Valaperti A, Berthonneche C, et al. Myeloid differentiation factor-88/interleukin-1 signaling controls cardiac fibrosis and heart failure progression in inflammatory dilated cardiomyopathy. Circ Res 2009; 105(9): 912-20.
29
Kong P, Christia P, Frangogiannis NG. The pathogenesis of cardiac fibrosis. Cell Mol Life Sci 2014; 71(4): 549-74.
30
Weber KT, Sun Y, Bhattacharya SK, Ahokas RA, Gerling IC. Myofibroblast-mediated mechanisms of pathological remodelling of the heart. Nat Rev Cardiol 2013; 10(1): 15-26.
31
Looi YH, Grieve DJ, Siva A, Walker SJ, Anilkumar N, Cave AC, et al. Involvement of Nox2 NADPH oxidase in adverse cardiac remodeling after myocardial infarction. Hypertension 2008; 51(2): 319-25.
32
ORIGINAL_ARTICLE
Right ventricular (RV) echocardiographic parameters in patients with pulmonary thromboembolism (PTE)
BACKGROUND: Acute pulmonary thromboembolism (PTE) is a common disease with a high mortality rate, and a variable and nonspecific clinical presentation. To detect the nonspecific signs and symptoms associated with this condition, several right ventricular (RV) echocardiographic parameters have been proposed as practical marker.METHODS: This cross-sectional study was performed on 93 patients with PTE diagnosed by computed tomography (CT) angiography, and 57 patients with negative PTE based on CT angiography. During the experiment, all patients underwent both transthoracic echocardiography (TTE) and multi-slice CT pulmonary angiography. Transthoracic echocardiography measurements were obtained as patients went through both experimental procedures. These measurements were later compared between the patients with and without PTE.RESULTS: Tricuspid annulus plain systolic excursion (TAPSE) (1.65 ± 0.09 vs. 2.00 ± 0.08 cm, P < 0.001) and left ventricular (LV) end-diastolic diameter (4.54 ± 0.26 vs. 5.40 ± 0.24 cm, P < 0.001) were significantly lower in patients with PTE as compared to patients without it. Whereas, RV end-diastolic and end-systolic diameters at the papillary muscle levels (3.41 ± 0.09 vs. 3.02 ± 0.12 cm, and 2.48 ± 0.08 vs. 2.16 ± 0.06 cm, respectively, P < 0.001 for both), and tricuspid valve (TV) annulus tissue Doppler imaging (TDI) measurements (6.02 ± 0.10 vs. 5.78 ± 0.14, P < 0.001) were significantly greater in patients with PTE. On the other hand, no significant difference was found between the two groups of patients regarding pulmonary artery pressure (PAP) (P = 0.416), and RV fractional shortening (P = 0.157). Moreover, our results indicated that RV/LV (cut-off point: 0.6898) had high sensitivity (93.5%), specificity (100%), positive predicting value (PPV) (100%), and negative predicting value (NPV) (90.4%) in diagnosing PTE.CONCLUSION: TTE may be valuable as a substitute diagnostic method for patients with PTE. This technique may also assist in detecting the severity of the illness, by evaluating RV/LV in cut-off point of 0.6898.
https://arya.mui.ac.ir/article_10626_1d1f5811353a111c2e6118e02f1f4c05.pdf
2018-04-21
78
84
10.22122/arya.v14i2.1494
Pulmonary Thromboembolism
Transthoracic Echocardiography
Computed Tomography Angiography
Javad
Shahabi
j.shahabi@yahoo.com
1
Heart Failure Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
LEAD_AUTHOR
Reihaneh
Zavar
2
Isfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
AUTHOR
Afshin
Amirpour
3
Cardiac Rehabilitation Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
AUTHOR
Mohammad
Bidmeshki
4
Hypertension Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
AUTHOR
Melinaz
Barati-Chermahini
5
Honours of Biology, York University, Toronto, Canada
AUTHOR
Alpert JS, Smith R, Carlson J, Ockene IS, Dexter L, Dalen JE. Mortality in patients treated for pulmonary
1
embolism. JAMA 1976; 236(13): 1477-80.
2
Carson JL, Kelley MA, Duff A, Weg JG, Fulkerson WJ, Palevsky HI, et al. The clinical course of pulmonary embolism. N Engl J Med 1992; 326(19): 1240-5.
3
Molina JA, Jiang ZG, Heng BH, Ong BK. Venous thromboembolism at the National Healthcare Group, Singapore. Ann Acad Med Singapore 2009; 38(6): 470-8.
4
van Beek EJ, Kuijer PM, Buller HR, Brandjes DP, Bossuyt PM, ten Cate JW. The clinical course of patients with suspected pulmonary embolism. Arch Intern Med 1997; 157(22): 2593-8.
5
Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: Clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet 1999; 353(9162): 1386-9.
6
Kasper W, Konstantinides S, Geibel A, Olschewski M, Heinrich F, Grosser KD, et al. Management strategies and determinants of outcome in acute major pulmonary embolism: Results of a multicenter registry. J Am Coll Cardiol 1997; 30(5): 1165-71.
7
Givi M, Sadeghi M, Garakyaraghi M, Eshghinezhad A, Moeini M, Ghasempour Z. Long-term effect of massage therapy on blood pressure in prehypertensive women. J Educ Health Promot 2018; 7: 54.
8
Rajabi F, Sadeghi M, Karbasian F, Torkan A. Is thromboprophylaxis effective in reducing the pulmonary thromboembolism? ARYA Atheroscler 2012; 8(1): 16-20.
9
Mirdamadi A, Dashtkar S, Kaji M, Pazhang F, Haghpanah B, Gharipour M. Dabigatran versus Enoxaparin in the prevention of venous thromboembolism after total knee arthroplasty: A randomized clinical trial. ARYA Atheroscler 2014; 10(6): 292-7.
10
Azari A, Bigdelu L, Moravvej Z. Surgical embolectomy in the management of massive and sub-massive pulmonary embolism: The results of 30 consecutive ill patients. ARYA Atheroscler 2015; 11(3): 208-13.
11
Ribeiro A, Lindmarker P, Juhlin-Dannfelt A, Johnsson H, Jorfeldt L. Echocardiography Doppler in pulmonary embolism: Right ventricular dysfunction as a predictor of mortality rate. Am Heart J 1997; 134(3): 479-87.
12
Horlander KT, Mannino DM, Leeper KV. Pulmonary embolism mortality in the United States, 1979-1998: An analysis using multiple-cause mortality data. Arch Intern Med 2003; 163(14): 1711-7.
13
Kaul S, Tei C, Hopkins JM, Shah PM. Assessment of right ventricular function using two-dimensional echocardiography. Am Heart J 1984; 107(3): 526-31.
14
Stein PD, Beemath A, Matta F, Weg JG, Yusen RD, Hales CA, et al. Clinical characteristics of patients with acute pulmonary embolism: Data from PIOPED II. Am J Med 2007; 120(10): 871-9.
15
Vitarelli A, Barilla F, Capotosto L, D'Angeli I, Truscelli G, De Maio M, et al. Right ventricular function in acute pulmonary embolism: A combined assessment by three-dimensional and speckle-tracking echocardiography. J Am Soc Echocardiogr 2014; 27(3): 329-38.
16
Gromadzinski L, Targonski R, Pruszczyk P. Assessment of right and left ventricular diastolic functions with tissue Doppler echocardiography in congestive heart failure patients with coexisting acute pulmonary embolism. Adv Clin Exp Med 2014; 23(3): 371-6.
17
Kjaergaard J, Akkan D, Iversen KK, Kober L, Torp-Pedersen C, Hassager C. Right ventricular dysfunction as an independent predictor of short- and long-term mortality in patients with heart failure. Eur J Heart Fail 2007; 9(6-7): 610-6.
18
Varol K, Gumus C, Yucel H, Sezer F, Seker E, Inci MF, et al. Correlation of right ventricular dysfunction on acute pulmonary embolism with pulmonary artery computed tomography obstruction index ratio (PACTOIR) and comparison with echocardiography. Jpn J Radiol 2015; 33(6): 311-6.
19
Lobo JL, Holley A, Tapson V, Moores L, Oribe M, Barron M, et al. Prognostic significance of tricuspid annular displacement in normotensive patients with acute symptomatic pulmonary embolism. J Thromb Haemost 2014; 12(7): 1020-7.
20
Ghio S, Recusani F, Klersy C, Sebastiani R, Laudisa ML, Campana C, et al. Prognostic usefulness of the tricuspid annular plane systolic excursion in patients with congestive heart failure secondary to idiopathic or ischemic dilated cardiomyopathy. Am J Cardiol
21
; 85(7): 837-42.
22
Hsiao SH, Chang SM, Lee CY, Yang SH, Lin SK, Chiou KR. Usefulness of tissue Doppler parameters for identifying pulmonary embolism in patients with signs of pulmonary hypertension. Am J Cardiol 2006; 98(5): 685-90.
23
Park JH, Kim JH, Lee JH, Choi SW, Jeong JO, Seong IW. Evaluation of right ventricular systolic function by the analysis of tricuspid annular motion in patients with acute pulmonary embolism. J Cardiovasc Ultrasound 2012; 20(4): 181-8.
24
Rudski LG, Lai WW, Afilalo J, Hua L, Handschumacher MD, Chandrasekaran K, et al. Guidelines for the echocardiographic assessment of the right heart in adults: A report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr 2010; 23(7): 685-713.
25
Caiani EG, Toledo E, MacEneaney P, Bardo D, Cerutti S, Lang RM, et al. Automated interpretation of regional left ventricular wall motion from cardiac magnetic resonance images. J Cardiovasc Magn Reson 2006; 8(3): 427-33.
26
Petkov R, Yamakova Y, Petkova E. TDI velocities of tricuspid annulus in patients with acute pulmonary embolism. Eur Respir J 2013; 42: P4101.
27
ORIGINAL_ARTICLE
Effect of cardiac rehabilitation on inflammation: A systematic review and meta-analysis of controlled clinical trials
BACKGROUND: This systematic review and meta-analysis aimed to assess the effect of cardiac rehabilitation (CR) on serum C-reactive protein (CRP) as an indicator of the inflammatory state and predictor of recurrent cardiovascular events.METHODS: PubMed, SCOPUS, Cochrane library, and Google Scholar databases were searched up to January 2014 for original articles which investigated the effect of CR on CRP among adult patients with previous cardiovascular events. The random effects model was used to assess the overall effect of CR on the variation in serum CRP levels.RESULTS: In the present systematic review and meta-analysis, 15 studies were included. The analysis showed that CR might significantly reduce high-sensitivity CRP (hs-CRP) levels [Difference in means (DM) = -1.81 mg/l, 95% confidence interval (CI): -2.65, -0.98; P = 0.004). However, the heterogeneity between studies was significant (Cochran's Q test, P < 0.001, I-squared = 84.9%). To find the source of variation, the studies were categorized based on study design (quality) and duration. The negative effect was higher among studies which followed their participants for 3 weeks or less (DM = -2.75 mg/l, 95% CI: -3.86, -1.64; P < 0.001) compared to studies which investigated the effect of CR for 3-8 weeks (DM = -0.89 mg/l, 95% CI: -1.35, -0.44; P < 0.001) and those which lasted more than 8 weeks (DM = -1.71 mg/l, 95% CI: -2.53, -0.89; P < 0.001). There was no evidence of heterogeneity when the categorization was based on the follow-up period.CONCLUSION: Both short- and long-term CR have resulted in improvement in serum hs-CRP levels. CR can be perceived as a beneficial tool to reduce inflammatory markers among patients with previous cardiac events.
https://arya.mui.ac.ir/article_10627_ef407825dd1d54bb49e33889e6c31530.pdf
2018-04-21
85
94
10.22122/arya.v14i2.1489
Cardiac Rehabilitation
Inflammation
C-Reactive Protein
Masoumeh
Sadeghi
1
Professor, Cardiac Rehabilitation Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
AUTHOR
Hossein
Khosravi-Broujeni
2
School of Medicine AND Menzies Health Institute, Griffith University, Southport, Queensland, Australia
AUTHOR
Amin
Salehi-Abarghouei
3
Assistant Professor, Nutrition and Food Security Research Center AND Department of Nutrition, School of Health, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
AUTHOR
Ramin
Heidari
4
Assistant Professor, Isfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
AUTHOR
Gholamreza
Masoumi
5
Associate Professor, Cardiac Anesthesiology Research Center, Chamran Heart Center Hospital, Isfahan University of Medical Sciences, Isfahan, Iran
AUTHOR
Hamidreza
Roohafza
hroohafza@gmail.com
6
Assistant Professor, Psychosomatic Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
LEAD_AUTHOR
Talaei M, Sarrafzadegan N, Sadeghi M, Oveisgharan S, Marshall T, Thomas GN, et al. Incidence of cardiovascular diseases in an Iranian population: The Isfahan Cohort Study. Arch Iran Med 2013; 16(3): 138-44.
1
Wilensky RL, Hamamdzic D. The molecular basis of vulnerable plaque: Potential therapeutic role for immunomodulation. Curr Opin Cardiol 2007; 22(6): 545-51.
2
Libby P. Inflammation and cardiovascular disease mechanisms. Am J Clin Nutr 2006; 83(2): 456S-60S.
3
van de Ree MA, Huisman MV, Princen HM, Meinders AE, Kluft C. Strong decrease of high sensitivity C-reactive protein with high-dose atorvastatin in patients with type 2 diabetes mellitus. Atherosclerosis 2003; 166(1): 129-35.
4
Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS, et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001; 344(26): 1959-65.
5
Ridker PM, Rifai N, Pfeffer MA, Sacks FM, Moye LA, Goldman S, et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1998; 98(9): 839-44.
6
Wenger NK, Froelicher ES, Smith LK, Ades PA, Berra K, Blumenthal JA, et al. Cardiac rehabilitation as secondary prevention. Agency for Health Care Policy and Research and National Heart, Lung, and Blood Institute. Clin Pract Guidel Quick Ref Guide Clin 1995; (17): 1-23.
7
Cesari F, Marcucci R, Gori AM, Burgisser C, Francini S, Sofi F, et al. Impact of a cardiac rehabilitation program and inflammatory state on endothelial progenitor cells in acute coronary syndrome patients. Int J Cardiol 2013; 167(5): 1854-9.
8
Hansen D, Dendale P, Raskin A, Schoonis A, Berger J, Vlassak I, et al. Long-term effect of rehabilitation in coronary artery disease patients: Randomized clinical trial of the impact of exercise volume. Clin Rehabil 2010; 24(4): 319-27.
9
Sarrafzadegan N, Rabiei K, Kabir A, Sadeghi M, Khosravi A, Asgari S, et al. Gender differences in risk factors and outcomes after cardiac rehabilitation. Acta Cardiol 2008; 63(6): 763-70.
10
Ghashghaei FE, Sadeghi M, Marandi SM, Ghashghaei SE. Exercise-based cardiac rehabilitation improves hemodynamic responses after coronary artery bypass graft surgery. ARYA Atheroscler 2012; 7(4): 151-6.
11
Sadeghi M, Garakyaraghi M, Khosravi M, Taghavi M, Sarrafzadegan N, Roohafza H. The impacts of cardiac rehabilitation program on echocardiographic parameters in coronary artery disease patients with left ventricular dysfunction. Cardiol Res Pract 2013; 2013: 201713.
12
Balen S, Vukelic-Damijani N, Persic V, Ruzic A, Miletic B, Samardiija M, et al. Anti-inflammatory effects of exercise training in the early period after myocardial infarction. Coll Antropol 2008; 32(1): 285-91.
13
Solov'ev AV, Ermolin GA, Ignashenkova GV, Dikov MM. Fibrinogen and fibrin degradation products in the blood of acute myocardial infarct patients at the hospital rehabilitation stage. Ter Arkh 1987; 59(10): 21-3.
14
Wosornu D, Allardyce W, Ballantyne D, Tansey P. Influence of power and aerobic exercise training on haemostatic factors after coronary artery surgery. Br Heart J 1992; 68(2): 181-6.
15
Conraads VM, Beckers P, Bosmans J, De Clerck LS, Stevens WJ, Vrints CJ, et al. Combined endurance/resistance training reduces plasma TNF-alpha receptor levels in patients with chronic heart failure and coronary artery disease. Eur Heart J 2002; 23(23): 1854-60.
16
Kim YJ, Shin YO, Bae JS, Lee JB, Ham JH, Son YJ, et al. Beneficial effects of cardiac rehabilitation and exercise after percutaneous coronary intervention on hsCRP and inflammatory cytokines in CAD patients. Pflugers Arch 2008; 455(6): 1081-8.
17
Shin YO, Bae JS, Lee JB, Kim JK, Kim YJ, Kim C, et al. Effect of cardiac rehabilitation and statin treatment on anti-HSP antibody titers in patients with coronary artery disease after percutaneous coronary intervention. Int Heart J 2006; 47(5): 671-82.
18
Aminlari A, Jazayeri SM, Bakhshandeh AR. Association of cardiac rehabilitation with improvement in high sensitive C-reactive protein post-myocardial infarction. Iran Red Crescent Med J 2012; 14(1): 49-50.
19
Lavie CJ, Morshedi-Meibodi A, Milani RV. Impact of cardiac rehabilitation on coronary risk factors, inflammation, and the metabolic syndrome in obese coronary patients. J Cardiometab Syndr 2008; 3(3): 136-40.
20
Madarame H, Kurano M, Fukumura K, Fukuda T, Nakajima T. Haemostatic and inflammatory responses to blood flow-restricted exercise in patients with ischaemic heart disease: A pilot study. Clin Physiol Funct Imaging 2013; 33(1): 11-7.
21
Milani RV, Lavie CJ, Mehra MR. Reduction in C-reactive protein through cardiac rehabilitation and exercise training. J Am Coll Cardiol 2004; 43(6): 1056-61.
22
Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003; 107(3): 363-9.
23
Ferratini M, Ripamonti V, Masson S, Grati P, Racca V, Cuccovillo I, et al. Pentraxin-3 predicts functional recovery and 1-year major adverse cardiovascular events after rehabilitation of cardiac surgery patients. J Cardiopulm Rehabil Prev 2012; 32(1): 17-24.
24
Fukuda T, Kurano M, Iida H, Takano H, Tanaka T, Yamamoto Y, et al. Cardiac rehabilitation decreases plasma pentraxin 3 in patients with cardiovascular diseases. Eur J Prev Cardiol 2012; 19(6): 1393-400.
25
Cesari F, Sofi F, Caporale R, Capalbo A, Marcucci R, Macchi C, et al. Relationship between exercise capacity, endothelial progenitor cells and cytochemokines in patients undergoing cardiac rehabilitation. Thromb Haemost 2009; 101(3): 521-6.
26
Kim C, Kim DY, Moon CJ. Prognostic influences of cardiac rehabilitation in Korean acute myocardial infarction patients. Ann Rehabil Med 2011; 35(3): 375-80.
27
Rankovic G, Milicic B, Savic T, Dindic B, Mancev Z, Pesic G. Effects of physical exercise on inflammatory parameters and risk for repeated acute coronary syndrome in patients with ischemic heart disease. Vojnosanit Pregl 2009; 66(1): 44-8.
28
Hansen D, Dendale P, Berger J, Onkelinx S, Reyckers I, Hermans A, et al. Importance of exercise training session duration in the rehabilitation of coronary artery disease patients. Eur J Cardiovasc Prev Rehabil 2008; 15(4): 453-9.
29
DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7(3): 177-88.
30
Egger M, Davey SG, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315(7109): 629-34.
31
Egger M, Davey-Smith G, Altman D. Systematic reviews in health care: Meta-analysis in context. Hoboken, NJ: John Wiley & Sons; 2001.
32
Pfutzner A, Forst T. High-sensitivity C-reactive protein as cardiovascular risk marker in patients with diabetes mellitus. Diabetes Technol Ther 2006; 8(1): 28-36.
33
Libby P, Ridker PM. Inflammation and atherosclerosis: Role of C-reactive protein in risk assessment. Am J Med 2004; 116(Suppl 6A): 9S-16S.
34
Gielen S, Adams V, Mobius-Winkler S, Linke A, Erbs S, Yu J, et al. Anti-inflammatory effects of exercise training in the skeletal muscle of patients with chronic heart failure. J Am Coll Cardiol 2003; 42(5): 861-8.
35
Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW. C-reactive protein in healthy subjects: Associations with obesity, insulin resistance, and endothelial dysfunction: A potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 1999; 19(4): 972-8.
36
ORIGINAL_ARTICLE
Distal accesses in the hand (two novel techniques) for percutaneous coronary angiography and intervention
BACKGROUND: Trans-radial and trans-ulnar accesses have been practiced and recommended as default and alternative techniques for coronary angiography and angioplasty in recent years. In this study, we present new innovative approaches using more distal access points, i.e. trans-snuff box and trans-palmar approaches.METHODS: We conducted dorsal hand access (trans-snuff box) for angiography and/or angioplasty on 235 patients, and trans-palmar access (superficial palmar branch of ulnar artery) on 175 patients in 3 hospitals in Isfahan City, Iran.RESULTS: In 221 patients out of 235 ones (94.1%) [men: 76.5%, age: 57.4 ± 10.4 (years); women: 23.5%, age: 62.4 ± 9.5 (years)], our procedure through snuff box (dorsal hand) was successfully performed. In 159 patients out of 175 ones (90.8%) [men: 76.0%, age: 58.1 ± 10.5 (years); women: 24.0%, age: 61.2 ± 9.6 (years)], our procedure through palmar artery was successfully performed. In total, the evaluated patients had mild pain (3.4% for snuff box, and 4.5% for palmar), ecchymosis in distal forearm (5.1% for snuff box, and 2.8% for palmar), with no major complications even one (amputation, infection, thrombosis, need for surgery, hand dysfunction, nerve palsy, and so forth). In addition, percutaneous coronary intervention (PCI) was done in 28.9% and 18.2% of cases via snuff box and palmar approaches, respectively. Meanwhile, hemostasis was very fast and easy with discharge time equivalent to other upper limb accesses.CONCLUSION: Although our procedures are at their early stages with about a follow-up period of 3-15 months, more researches are recommended to be conducted in forthcoming months and years, and this new innovative approaches could be suggested safe, feasible, and reliable with low complications.
https://arya.mui.ac.ir/article_10628_48dc3c2ed66877fa95a5f1fcac7445d7.pdf
2018-04-21
95
100
10.22122/arya.v14i2.1743
Coronary Angiography
Coronary Angioplasty
Trans-Palmar Approach
Trans-Snuff Box Approach
Distal Accesses
Novel Accesses
Farshad
Roghani-Dehkordi
frdehkordi@gmail.com
1
Associate Professor, Interventional Cardiology Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
LEAD_AUTHOR
Omid
Hashemifard
2
Cardiologist, Isfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
AUTHOR
Masoumeh
Sadeghi
3
Professor, Cardiac Rehabilitation Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
AUTHOR
Rohollah
Mansouri
4
Hypertension Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
AUTHOR
Mehdi
Akbarzadeh
5
Heart Failure Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
AUTHOR
Asieh
Dehghani
6
School of Nursing and Midwifery AND Young Researchers and Elite Club, Isfahan (Khorasgan) Branch, Islamic Azad University, Isfahan, Iran
AUTHOR
Mojtaba
Akbari
7
Department of Biostatistics, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
AUTHOR
Liu J, Fu XH, Xue L, Wu WL, Gu XS, Li SQ. A comparative study of transulnar and transradial artery access for percutaneous coronary intervention in patients with acute coronary syndrome. J Interv Cardiol 2014; 27(5): 525-30.
1
Sallam M, Al-Riyami A, Misbah M, Al-Sukaiti R, Al-Alawi A, Al-Wahaibi A. Procedural and clinical utility of transulnar approach for coronary procedures following failure of radial route: Single centre experience. J Saudi Heart Assoc 2014; 26(3): 138-44.
2
Kiemeneij F. Left distal transradial access in the
3
anatomical snuffbox for coronary angiography (ldTRA) and interventions (ldTRI). EuroIntervention 2017; 13(7): 851-7.
4
Roghani F, Shirani B, Hashemifard O. The effect of low dose versus standard dose of arterial heparin on vascular complications following transradial coronary angiography: Randomized controlled clinical trial. ARYA Atheroscler 2016; 12(1): 10-7.
5
Costa F, van Leeuwen MA, Daemen J, Diletti R, Kauer F, van Geuns RJ, et al. The rotterdam radial access research: Ultrasound-based radial artery evaluation for diagnostic and therapeutic coronary procedures. Circ Cardiovasc Interv 2016; 9(2): e003129.
6
Kumar AJ, Jones LE, Kollmeyer KR, Feldtman RW, Ferrara CA, Moe MN, et al. Radial artery access for peripheral endovascular procedures. J Vasc Surg 2017; 66(3): 820-5.
7
Maniotis C, Koutouzis M, Andreou C, Lazaris E, Tsiafoutis I, Zografos T, et al. Transradial approach for cardiac catheterization in patients with negative Allen's test. J Invasive Cardiol 2015; 27(9): 416-20.
8
Rao SV, Kedev S. Approaching the post-femoral era for coronary angiography and intervention. JACC Cardiovasc Interv 2015; 8(4): 524-6.
9
Roghani-Dehkordi F, Hadizadeh M, Hadizadeh F. Percutaneous trans-ulnar artery approach for coronary angiography and angioplasty; A case series study. ARYA Atheroscler 2015; 11(5): 305-9.
10
Roghani F, Tajik MN, Khosravi A. Compare complication of classic versus patent hemostasis in transradial coronary angiography. Adv Biomed Res 2017; 6: 159.
11
Valsecchi O, Vassileva A, Musumeci G, Rossini R, Tespili M, Guagliumi G, et al. Failure of transradial approach during coronary interventions: Anatomic considerations. Catheter Cardiovasc Interv 2006; 67(6): 870-8.
12
Dehghani P, Mohammad A, Bajaj R, Hong T, Suen CM, Sharieff W, et al. Mechanism and predictors of failed transradial approach for percutaneous coronary interventions. JACC Cardiovasc Interv 2009; 2(11): 1057-64.
13
Biondi-Zoccai G, Sciahbasi A, Bodi V, Fernandez- Portales J, Kanei Y, Romagnoli E, et al. Right
14
versus left radial artery access for coronary procedures: an international collaborative systematic review and meta-analysis including 5 randomized trials and 3210 patients. Int J Cardiol 2013; 166(3): 621-6.
15
Dahal K, Rijal J, Lee J, Korr KS, Azrin M. Transulnar versus transradial access for coronary angiography or percutaneous coronary intervention: A meta-analysis of randomized controlled trials. Catheter Cardiovasc Interv 2016; 87(5): 857-65.
16
Gokhroo R, Kishor K, Ranwa B, Bisht D, Gupta S, Padmanabhan D, et al. Ulnar artery interventions non-inferior to radial approach: Ajmer ulnar artery (AJULAR) intervention working group study results. J Invasive Cardiol 2016; 28(1): 1-8.
17
Roghani-Dehkordi F. Merits of more distal accesses in the hand for coronary angiography and intervention. Proceedings of the 4th International Cardiovascular Joint Congress in Isfahan; 2016 Nov. 24-25; Isfahan, Iran.
18
Kaledin A, Kochanov I, Podmetin P, Ardeev VN. Distal radial artery in endovascular interventions [Online]. [cited 2017]; Available from: URL:
19
https://www.researchgate.net/publication/319162208
20
Babunashvili A. Novel snuff-box technique for trans-radial approach: Let’s go distal. Proceedings of the Aim-Radial 2016; 2016 Sep. 23-22; Budapest, Hungary.
21
Latsios G, Toutouzas K, Synetos A, Vogiatzi G, Papanikolaou A, Tsiamis E, et al. Left distal radial artery for cardiac catheterization: Insights from our first experience. Hellenic J Cardiol 2018.
22
McNamara MG, Butler TE, Sanders WE, Pederson WC. Ischaemia of the index finger and thumb secondary to thrombosis of the radial artery in the anatomical snuffbox. J Hand Surg Br 1998; 23(1): 28-32.
23
ORIGINAL_ARTICLE
Trifascicular block as primary presentation of the cardiac amyloidosis; A rare case report
BACKGROUND: Amyloidosis is a severe systemic disorder produces by the accumulation of inappropriately amyloid deposition in tissues. Cardiac involvement, as a main type of amyloidosis, has a major impact on prognosis. We describe a biopsy-proven cardiac amyloidosis in an old man with unexpected presentation.CASE REPORT: A 70-year-old man, with a complaint of severe weakness, lightheadedness, and lower limb paresthesia, was admitted to the emergency department. Electrocardiography revealed right bundle branch block and Trifascicular block. Echocardiography study showed a moderately increased thickness of left ventricular wall with concentric pattern as well. Laboratory investigations including serum and urine electrophoresis, and serum free light chain examination as immunofixation assay revealed that κ chains predominated over λ chains in a ratio of 3:2. Our patient with final diagnosis of amyloid light-chain (AL) amyloidosis underwent chemotherapy with melphalan combined with high-dose dexamethasone, CPHPC and monoclonal antibodies for 2 weeks.CONCLUSION: It shows that rapid diagnosis of AL amyloidosis can enhance the prognosis. Applying an optimal strategy for the treatment leads to effective therapy, too.
https://arya.mui.ac.ir/article_10621_f7b1b4dd8dc82d895436c2cf4cc35169.pdf
2018-04-21
101
104
10.22122/arya.v14i2.1676
Amyloidosis
Bundle Branch Block
Echocardiography
Mohsen
Yaghubi
n.m.yaghubi@gmail.com
1
MSc Student, Student Research Committee AND Department of Cardiac Surgery, Mashhad University of Medical Sciences, Mashhad, Iran
AUTHOR
Hossein
Dinpanah
2
Assistant Professor, Department of Emergency, Dey 9th Hospital, Torbat Heydariyeh University of Medical Sciences, Torbat Heydariyeh, Iran
AUTHOR
Fahimeh
Ghanei- Motlagh
3
Department of Obstetrics and Gynecology, Dey 9th Hospital, Torbat Heydariyeh University of Medical Sciences, Torbat Heydariyeh, Iran
AUTHOR
Samaneh
Kakhki
4
Assistant Professor, Department of Pharmacology, Torbat Heydariyeh University of Medical Sciences, Torbat Heydariyeh, Iran
AUTHOR
Reza
Ghasemi
rezaghasemi152@yahoo.com
5
Assistant Professor, Department of Cardiology, Torbat Heydariyeh University of Medical Sciences, Torbat Heydariyeh, Iran
LEAD_AUTHOR
Bunker D, Gorevic P. AA amyloidosis: Mount Sinai experience, 1997-2012. Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine 2012; 79(6): 749-56.
1
Dubrey SW, Hawkins PN, Falk RH. Amyloid diseases of the heart: Assessment, diagnosis, and referral. Heart 2011; 97(1): 75-84.
2
Falk RH. Diagnosis and management of the cardiac amyloidoses. Circulation 2005; 112(13): 2047-60.
3
Fikrle M, Palecek T, Kuchynka P, Nemecek E, Bauerova L, Straub J, et al. Cardiac amyloidosis: A comprehensive review. Cor et Vasa 2013; 55(1): e60-e75.
4
Koyama J, Falk RH. Prognostic significance of strain Doppler imaging in light-chain amyloidosis. JACC Cardiovasc Imaging 2010; 3(4): 333-42.
5
Palladini G, Lavatelli F, Russo P, Perlini S, Perfetti V, Bosoni T, et al. Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL. Blood 2006; 107(10): 3854-8.
6
Merlini G, Seldin DC, Gertz MA. Amyloidosis:
7
Pathogenesis and new therapeutic options. J Clin Oncol 2011; 29(14): 1924-33.
8
Mohty D, Damy T, Cosnay P, Echahidi N, Casset-Senon D, Virot P, et al. Cardiac amyloidosis: Updates in diagnosis and management. Arch Cardiovasc Dis 2013; 106(10): 528-40.
9
Nordlinger M, Magnani B, Skinner M, Falk RH. Is elevated plasma B-natriuretic peptide in amyloidosis simply a function of the presence of heart failure? Am J Cardiol 2005; 96(7): 982-4.
10
Palladini G, Merlini G. Current treatment of AL amyloidosis. Haematologica 2009; 94(8):
11
Reyners AK, Hazenberg BP, Reitsma WD, Smit AJ. Heart rate variability as a predictor of mortality in patients with AA and AL amyloidosis. Eur Heart J 2002; 23(2): 157-61.
12
Selvanayagam JB, Hawkins PN, Paul B, Myerson SG, Neubauer S. Evaluation and management of the cardiac amyloidosis. J Am Coll Cardiol 2007; 50(22): 2101-10.
13
ORIGINAL_ARTICLE
Journal Index
Click to download the index of this issue.
https://arya.mui.ac.ir/article_10620_895b4a5c9fa5003d91e60c083d1b036f.pdf
2018-03-01
10.22122/arya.v14i2.1841
Index
Journal
arya@mui.ac.ir
1
LEAD_AUTHOR